Company* (Country; Symbol) |
Company* (Country; Symbol) |
Type/Product Area |
Terms/Details (Date) |
ACE BioSciences A/S* (Denmark) |
Crucell NV (the Netherlands; CRXL) |
Crucell licensed bacterial antigens to accelerate its bacterial antibody discovery program |
The license was granted by ACE and the Brigham and Women's Hospital; terms of the deal were not disclosed (11/2) |
ActiveSight (unit of Rigaku Americas Corp.) |
Inpharmatica Ltd.* (UK) |
ActiveSight will provide structural biology services to Inpharmatica |
The deal focuses on co-crystallography by ActiveSight of certain Inpharmatica small molecules with a human drug target protein; ActiveSight is entitled to up-front and milestone payments (11/17) |
ActiveSight (unit of Rigaku Americas Corp.) |
Ambit Biosciences Corp.* |
Protein crystallography services agreement to advance drug discovery at Ambit |
The deal covers the co-crystallization of Ambit molecules with proteins expressed by ActiveSight; terms were not disclosed (11/1) |
Affitech A/S* (Norway) |
XOMA Ltd. (XOMA) |
Collaboration and cross-license agreement covering antibody-related technologies |
Affitech gets a license to use XOMA's bacterial cell expression technology; XOMA gets rights to use Affitech's naïve antibody library; terms were not disclosed (11/29) |
Affymetrix Inc. (AFFX) |
Vita Genomics* (Taiwan) |
Vita got nonexclusive access to Affymetrix microarray technology to develop and market in vitro diagnostics |
The license covers tests for alpha interferon treatment response in hepatitis patients, and for early onset and allergic asthma in infants and young children (12/26) |
Affymetrix Inc. (AFFX) |
PathWork Informatics Inc.* |
PathWork got long-term, nonexclusive access to microarray technology from Affymetrix |
PathWork plans to develop and market in vitro diagnostic tests for cancer under the Powered by Affymetrix program; terms were not disclosed (11/1) |
Amarin Corp. plc (UK; AMRN) |
Multicell Technologies Inc. (OTC BB:MCET) |
Multicell acquired exclusive rights to LAX-202 (now MCT-125) for treating fatigue in multiple sclerosis patients |
Amarin is entitled to up-front, milestone and royalty payments from Multicell; it got the product through its acquisition of of Laxdale Ltd. in 2004 (1/3) |
Argenta Discovery Ltd.* (UK) |
Genentech Inc. (NYSE:DNA) |
Two-year deal to use Argenta technologies to discover compounds against a Genentech drug target |
Terms of the deal were not disclosed, but do provide options to expand the relationship (12/15) |
Avigen Inc. (AVGN) |
Genzyme Corp. (GENZ) |
Genzyme is acquiring all Avigen assets related to adeno-associated vectors, except those related to pain |
Avigen gets $12M up front for the gene therapy program and is eligible to receive milestone and royalty payments on resulting products (12/21) |
BioCyDex Inc.* (Canada) |
BioMS Medical Corp. (Canada; TSE:MS) |
BioMS purchased additional equity in BioCyDex, increasing its ownership stake to 49% |
BioCyDex is developing technology to deliver antiviral and cancer compounds directly into cells; terms of the deal were not disclosed (1/6) |
Biolex Therapeutics Inc.* |
Kringle Pharma Inc.* (Japan) |
Biolex will use its LEX System to create a commercial line for Kringle's NK4 protein |
NK4 is an elastase-generated fragment of hepatocyte growth factor, being developed for cancers; terms were not disclosed (10/27) |
BioSpecifics Technologies Corp.* |
Auxilium Pharmaceuticals Inc. (AUXL) |
Auxilium exercised its option expanding its rights to an additional indication for the injectable enzyme AA4500 |
Auxilium gets exclusive rights to the product for treating frozen shoulder syndrome; it already had rights to the drug in treating Dupuytren's and Peyronie's diseases (12/20) |
Biota Holdings Ltd. (Australia; ASX:BTA) |
MedImmune Inc. (MEDI) |
Deal to develop Biota's small-molecule compounds designed to prevent and treat respiratory syncytial virus |
Biota gets $5M up front and R&D payments, and could get up to $107.5M in milestone payments, as well as royalties on sales; Biota retained marketing rights in Australia, China and Southeast Asia (12/14) |
Bio3 Research Srl* (Italy) and Creabilis Therapeutics SpA* (Italy) |
Cephalon Inc. (CEPH) |
Deal to evaluate the compound K252a for treating psoriasis and restenosis |
All three companies have certain rights to the compound; Cephalon gets an exclusive option to develop and sell resulting products (12/1) |
BioTrove Inc.* |
Sirtris Pharmaceuticals Inc.* |
BioTrove will perform high-throughput screening on Sirtris targets |
BioTrove will use its RapidFire Lead Discovery service in the effort, which represents an expansion of an existing deal (11/9) |
Caprion Pharmaceuticals Inc.* |
ICOS Corp. (ICOS) |
Caprion will identify pharmaco-dynamic markers in plasma relating to preclinical oncology programs at ICOS |
Caprion will use its CellCarta proteomics discovery platform in the deal, its second with ICOS; terms were not disclosed (1/18) |
Caprion Pharmaceuticals Inc.* |
ImClone Systems Inc. (IMCL) |
Deal under which ImClone may exclusively license antibody protein targets for use in drug development |
ImClone can get rights to any target it selects; Caprion is entitled to an up-front payment, license fees, milestone payments and royalties on any resulting sales (1/10) |
ChemDiv Inc.* |
ProQinase GmbH* (Germany) |
They formed a partnership for the discovery and preclinical development of kinase inhibitors |
They will share development costs and any revenues from the planned out-licensing of optimized leads (11/7) |
Collegium Pharmaceuticals Inc.* |
Accentia Bio-pharmaceuticals Inc. (ABPI) |
Accentia got U.S. rights to an intranasal steroid product for treating allergic rhinitis |
Collegium plans to file a supplemental NDA in 2006 for the aqueous nasal spray formulation; terms of the deal were not disclosed (12/6) |
Cresset BioMolecular Discovery Ltd.* (UK) |
Galapagos NV (Belgium; Euronext:GLPG) |
Deal to develop compound libraries based on Cresset's molecular fields software |
Galapagos division BioFocus has an option to license the technology for medicinal chemistry projects for itself and third parties (12/15) |
Crucell NV (the Netherlands; CRXL) |
XOMA Ltd. (XOMA) |
XOMA got a nonexclusive STAR research license for producing monoclonal antibodies and other proteins |
Terms of the deal were not disclosed (1/5) |
Crucell NV (the Netherlands; CRXL) and DSM Biologics (the Netherlands) |
ZyStor Therapeutics Inc.* |
ZyStor got rights to evaluate the PER.C6 cell line for use in the manufacturing of a specific therapeutic protein |
Terms of the deal were not disclosed (12/21) |
Crucell NV (the Netherlands; CRXL) |
Genzyme Corp. (GENZ) |
Genzyme got a nonexclusive research license for producing monoclonal antibodies |
Details on the STAR license were not disclosed (12/19) |
Crucell NV (the Netherlands; CRXL) |
Vakzine Projekt Management GmbH* (Germany) |
VPM got rights to use the PER.C6 cell line to develop a vaccine and diagnostics for an undisclosed infectious disease |
Crucell gets a research license fee and annual maintenance fees; further terms were not disclosed (12/8) |
De Novo Pharmaceuticals Ltd.* (UK) |
Genzyme Corp. (GENZ) |
De Novo will apply its molecular structure-generating technology to a target of interest to Genzyme |
Terms of the deal were not disclosed (1/17) |
Dyax Corp. (DYAX) |
Debiopharm SA* (Switzerland) |
They restructured deal for developing Dyax's DX-890, an inhibitor of neutrophil elastase, for treating pulmonary disorders |
Debiopharm gets exclusive rights to a native form of DX-890 in cystic fibrosis and acute respiratory distress syndrome; Dyax gets a milestone payment and retains rights to milestones and royalties from the DX-890 programs (12/20) |
Eidogen-Sertanty Inc.* |
Cephalon Inc. (CEPH) |
Cephalon gained access to discovery informatics software and databases |
Cephalon will use the software to support small-molecule discovery projects in its neurology and oncology programs; terms were not disclosed (1/5) |
Eidogen-Sertanty Inc.* |
Kalypsys Inc.* |
Collaboration focused on the discovery of small-molecule compounds for anti-inflammatory indications |
Eidogen will design a virtual library of compounds expected to be active against a Kalypsys target; terms of the deal were not disclosed (12/14) |
4AZA Bioscience NV* (Belgium) |
Gilead Sciences Inc. (GILD) |
Deal to develop compounds discovered by 4AZA for treatment of hepatitis C virus infection |
4AZA gets an up-front payment and equity investment from Gilead, which gets world-wide rights; 4AZA also will get research funding and could get milestone and royalty payments (11/30) |
Galapagos NV (Belgium; Euronext:GLPG) |
Prolysis Ltd.* (UK) |
They extended deal from earlier in 2005 focused on a Prolysis program in antibiotic resistance |
Galapagos division BioFocus is doing lead-optimization work to identify dual enzyme inhibitors that overcome the problem of resistance; Prolysis will fund work through 2006 (12/30) |
Galapagos NV (Belgium; Euronext:GLPG) |
Amgen Inc. (AMGN) |
They extended deal under which Galapagos division BioFocus is providing biology and chemistry services for Amgen |
The deal will run through 2006 and focus on Amgen's ion channel lead discovery programs; Galapagos gets $2.3M up front and up to a total of $30M in access and researches fees, milestone payments and bonuses (12/7) |
Galapagos NV (Belgium; Euronext:GLPG) |
Senexis Ltd.* (UK) |
Expanded deal to optimize Senexis compounds being developed for Alzheimer's disease |
Galapagos division BioFocus will provide medicinal chemistry services to Senexis; terms of the deal were not disclosed (12/2) |
Galapagos NV (Belgium; Euronext:GLPG) |
Idenix Pharmaceuticals Inc. (IDIX) |
Galapagos division BioFocus will provide compound collections and medicinal chemistry services to Idenix |
The focus is on hepatitis and HIV programs at Idenix; Galapagos can earn up to $2.5M over the two-year collaboration (11/24) |
Galileo Pharmaceuticals Inc.* |
Edison Pharmaceuticals Inc.* |
They entered technology transfer and screening agreements |
Details were not disclosed; as part of the deal, Galileo gained an equity stake in Edison (11/29) |
Genedata AG* (Switzerland) |
TransTech Pharma Inc.* |
TransTech licensed the Genedata Screener high-throughput screening analysis software |
TransTech will use the technology to enhance small-molecule drug development; terms of the multiyear deal were not disclosed (12/14) |
Genedata AG* (Switzerland) |
Neurocrine Biosciences Inc. (NBIX) |
Neurocrine licensed the Genedata Expressionist gene expression analysis system |
Neurocrine will use the technology for bio-marker discovery and in silico prediction, in discovery programs focused on neurological and endocrine-related diseases (12/7) |
Genedata AG* (Switzerland) |
Signature Diagnostics AG* (Germany) |
Signature licensed Genedata software to help identify gene expression profiles |
Terms of the license to the Genedata Expressionist software solution were not disclosed (11/1) |
GeneGo Inc.* |
Velcura Therapeutics Inc.* |
Velcura licensed GeneGo's MetaCore database product under a multiyear deal |
Velcura will use the technology for analysis of gene expression and proteomic and other data related to bone formation (11/9) |
GenOway* (France) |
Invitrogen Corp. (IVGN) |
Deal to create a services platform offering RNAi vector design through creation of RNAi transgenic rodent models |
Each company will contribute technology to the effort; revenues from the co-marketing deal would be shared on an undisclosed basis (12/15) |
GenVec Inc. (GNVC) |
Mytogen Inc.* |
Mytogen acquired GenVec's myoblast cell therapy program; it will keep most employees who managed the program |
GenVec is eligible to receive milestone and royalty payments in the deal; the technology is being developed to treat congestive heart failure (12/29) |
GPC Biotech AG (Germany; GPCB) |
Pharmion Corp. (PHRM) |
Pharmion got rights to the Phase III cancer product satraplatin in Europe, Turkey, the Middle East, Australia and New Zealand |
GPC gets $37.1M up front; they will share development costs; GPC could get $30.5M in milestone payments, and up to $75M more for up to five subsequent EMEA approvals; another $105M in sales milestones could be paid, as well as royalties starting at 26% (12/20) |
Human Genome Sciences Inc. (HGSI) |
PDL BioPharma Inc. (PDLI) |
PDL got certain exclusive rights to an undisclosed target antigen discovered by HGSI |
HGSI is entitled to an up-front licensing fee, development milestone payments and royalties on resulting sales; HGS also got access to PDL's antibody humanization technology (1/10) |
Human Genome Sciences Inc. (HGSI) |
Amgen Inc. (AMGN) |
Amgen got exclusive rights to develop products based on a gene discovered by HGS; it also got nonexclusive diagnostic rights |
The gene may have autoimmune, immune system and cancer applications; HGS gets an up-front payment and annual fees, as well as potential milestone and royalty payments (1/9) |
Human Genome Sciences Inc. (HGSI) |
CoGenesys* |
CoGenesys got rights to develop products based on certain HGS genes, and to albumin-fusion technology; it is being spun out of HGS |
HGS also is providing a $10M startup loan; HGS gets an up-front payment and would get a portion of any revenues; it also retains a right of first refusal to develop certain products that may be developed (12/13) |
IDM Pharma Inc. (IDMI) |
Pharmexa A/S (Denmark; CSE:PHARMX) |
IDM is selling Pharmexa assets related to its infectious disease programs |
IDM is getting $12M in cash and certain rights to use Padre and Epitope Identification System technologies that were included in the deal (11/25) |
Illumina Inc. (ILMN) |
Genizon BioSciences Inc.* (Canada) |
Genizon adopted Illumina's whole-genome genotyping technology for disease-association research |
Terms of the deal were not disclosed (1/12) |
ImmunoGen Inc. (IMGN) |
Genentech Inc. (NYSE:DNA) |
Genentech got exclusive rights to use Tumor-Activated Prodrug technology with antibodies to an undisclosed target |
The deal marks Genentech's fourth license to the technology; ImmunoGen gets a $1M license payment and could receive milestone and royalty payments (12/13) |
Ingenuity Systems Inc.* |
Avalon Pharmaceuticals Inc. (AVRX) |
Avalon licensed Ingenuity's Pathways Analysis 3.0 software |
Avalon will use the technology in drug and target discovery; terms were not disclosed (1/10) |
Intercell AG (Austria; VSE:ICLL) |
Pelias Biomedical Development AG* (Austria) |
Pelias gained rights to certain antigens that target pathogens in hospital infections |
Intercell gets an up-front payment and would get royalties on sales; it also holds a major stake in Pelias, which it helped establish (12/9) |
InterMune Inc. (ITMN) |
Targanta Therapeutics Inc.* |
Targanta acquired oritavancin, an antibiotic that has completed two Phase III trials |
InterMune is entitled to $9M in up-front and milestone payments and got a promissory note worth up to $25 million; the note will convert into Targanta stock as objectives are reached (12/27) |
Isogenica Ltd.* (UK) |
Amgen Inc. (AMGN) |
Isogenica will use its CIS display technology to select peptide candidates to certain Amgen targets |
Isogenica will get research fees and could receive milestone and royalty payments on resulting products (11/7) |
Kreatech Biotechnology BV* (the Netherlands) |
Immunicon Corp. (IMMC) |
Imunicon got rights to use Kreatech's Universal Linkage System technology |
Immunicon will use the technology in a program for detecting cancer cells; terms of the deal were not disclosed (1/5) |
Lexicon Genetics Inc. (LEXG) |
Genentech Inc. (NYSE:DNA) |
Lexicon will perform research on a number of targets from Genentech's Secreted Protein Discovery Initiative program |
Lexicon is entitled to $25M in up-front, milestone and research funding during the three-year research phase; Lexicon also could receive development milestones, and would get royalties on any sales, or share in costs and profits (12/1) |
Lexicon Genetics Inc. (LEXG) |
Taconic Farms Inc.* |
Deal for the marketing and licensing of certain knockout mice made by Lexicon |
Taconic will provide breeding services and licenses for more than 1,000 lines and distribute the knockout mice (11/11) |
Macrozyme BV* (the Netherlands) |
Genzyme Corp. (GENZ) |
Collaboration to explore Macrozyme's small-molecule library as inhibitors of glucosylceramide synthase |
The initial focus is on diabetes and insulin resistance; Macrozyme will get research funding and could get milestone and royalty payments (11/24) |
Matrix Pharma Inc.* |
Safetek International Inc. (OTC BB:SFIN) |
Safetek got an option to develop oral, direct thrombin inhibitors from Matrix |
The option runs until March 31, 2006; Matrix is entitled to milestone payments in the deal (1/11) |
Micromet AG* (Germany) |
Haptogen Ltd.* (UK) |
Haptogen got research access to single-chain antibody technology from Micromet |
The deal was made under Micromet's exclusive marketing deal with Enzon Pharmaceuticals Inc., which will get a share of the proceeds (1/18) |
Micromet AG* (Germany) |
Alligator Bioscience AB* (Sweden) |
Alligator got research access to single-chain antibody technology from Micromet |
The deal was made under Micromet's exclusive marketing deal with Enzon Pharmaceuticals Inc., which will get a share of the proceeds (1/18) |
Micromet AG* (Germany) |
MedImmune Inc. (MEDI) |
They initiated a second program, against an undisclosed target antigen |
The companies are using Micromet's BiTE platform in the drug discovery effort; terms were not disclosed (11/21) |
Migenix Inc. (Canada; TSE:MGI) |
Cutanea Life Sciences Inc.* |
Cutanea got rights to develop and market MX-594AN for a number of dermatological indications |
Migenix gets an up-front payment and up to $21M in development and sales milestones, as well as royalties on any sales; Phase II trials in acne have been completed (12/8) |
MorphoSys AG (Germany; FSE:MOR) |
Serologicals Corp. (SERO) |
Serologicals subsidiary Chemicon International Inc. will distribute HuCAL-based research antibodies |
MorphoSys will develop antibodies against Chemicon targets; MorphoSys will get payments for antibody generation, other potential fees and royalties on all products under the three-year deal (1/10) |
Morphotek Inc.* |
Invitrogen Corp. (IVGN) |
Invitrogen acquired Morphotek's cell line evolution service business |
Morphotek retained rights to use its antibody and basic evolution technologies for internal development; terms of the deal were not disclosed (1/5) |
NicOx SA Pharmaceuticals Eurolist: NICOX) |
Topigen Inc.* (Canada) |
Topigen got North American rights to NCX 1020, a Phase IIa drug for treating chronic obstructive pulmonary disease and other respiratory disorders |
NicOx gets |2M up front and up to |52.9M (France; in milestone and commercial success fees, in addition to a share of future revenues; that total includes fees that could be received if Topigen exercises its option to get rights in the rest of the world (10/27) |
Novavax Inc. (NVAX) |
IGI Inc. (AMEX:IG) |
IGI extended for 10 years its exclusive license to use certain Novavax technologies |
IGI's rights to the Novasome lipid vesicle encapsulation technology, micellar nanoparticles and the Ultrasponge technology cover a number of applications (12/13) |
OncoMab GmbH* (Germany) |
Acceptys Inc.* |
The companies combined their human antibody therapeutic pipelines and their R&D operations |
Acceptys got rights to evaluate, acquire and develop all eight lead antibody cancer candidates from the OncoMab pipeline, which will be jointly developed (12/23) |
Perlegen Sciences Inc.* |
Genentech Inc. (NYSE:DNA) |
Collaboration to study the genetics of cancer |
They will use Perlegen's high-throughput oligonucleotide array approach in the deal, terms of which were not disclosed (1/6) |
Phospho-Solutions LLC* |
Vitro Diagnostics Inc. (OTC BB:VODG) |
Deal to characterize intra-cellular signaling mechanisms that regulate stem cell growth and differentiation |
Terms of the deal were not disclosed (1/11) |
PIramed Ltd.* (UK) |
Genentech Inc. (NYSE:DNA) |
Collaboration to develop PIramed compounds targeting PI 3-kinase, an extracellular enzyme implicated in cancers |
PIramed gets an up-front payment and could receive up to $230M in milestone payments up through product approval, as well as research funding and royalties on any sales (11/30) |
Protein Sciences Corp.* |
Diamyd Medical AB (Sweden; SSE: DIAMB) |
Deal for the U.S. development of Diamyd's therapeutic diabetes vaccine named Diamyd |
Protein Sciences will prepare an IND filing with the FDA for the vaccine and will manufacture clinical materials; separately, Diamyd made an equity investment in Protein Sciences (1/9) |
PR Pharmaceuticals Inc.* |
OSI Pharmaceuticals Inc. (OSPI) |
Deal to develop a sustained-release formulation of OSI's approved drug Macugen |
OSI got rights to use PRP's ProPhase encapsulation technology for eye diseases; PR gets an up-front payment, program support and potential milestone and royalty payments (1/11) |
RheoGene Inc.* |
Serologicals Corp. (SERO) |
Serologicals got a semi-exclusive license to RheoGene's RheoSwitch System and related technologies |
Serologicals subsidiary Chemicon International Inc. got rights to use the technology in its research product lines focused on specialty research markets; terms were not disclosed (11/28) |
Savient Pharmaceuticals Inc. (SVNTE) |
Indevus Pharmaceuticals Inc. (IDEV) |
Indevus acquired Delatestryl, an injectable testosterone product approved for male hypogonadism |
Savient gets an initial payment of $5M and a portion of sales for three years; Indevus also will purchase about $1.9M of inventory (12/13) |
Stem Cell Sciences plc (UK; AIM:STEM) |
Lexicon Genetics Inc. (LEXG) |
Lexicon gained increased rights to Internal Ribosome Entry Site technology for genetically modified mice |
SCS gets an up-front payment and will share revenues from sublicenses; it also got certain rights to Lexicon's gene targeting technology for use in stem cell and progenitor cell lines (11/3) |
Telomolecular Corp.* |
New Life Scientific Inc. (OTC BB:NWLF) |
Collaboration to develop products that treat aging and age-related diseases |
They plan to explore potentially synergistic technologies in the deal, terms of which were not disclosed (12/6) |
TheraCarb Inc.* (Canada) |
BioVeris Corp. (BIOV) |
BioVeris got an option to license exclusive rights to a vaccine candidate for Candida albicans |
BioVeris paid $75,000, and will sponsor $170,000 of research at TheraCarb, which would be entitled to license fees, milestone payments and royalties if the option is exercised (1/18) |
Tranzyme Pharma Inc.* |
Open Biosystems Inc.* |
OBI licensed exclusive rights to human-based translentiviral gene expression technology |
OBI also will assume Tranzyme's operations in Birmingham, Ala.; Tranzyme will get annual payments and royalties on any resulting sales (11/14) |
Tripep AB (Sweden; SSE:TPEP) |
Inovio Biomedical Corp. (AMEX:INO) |
Deal to develop a therapeutic vaccine for hepatitis C virus using Tripep's HCV antigen and Innovio's Medpulser DNA Delivery System |
Each will fund a portion of upcoming trials and share any profits according to their contribution; Inovio initially gets 33% ownership in the product, with an option to increase it to 50% (1/17) |
Xencor Inc.* |
MedImmune Inc. (MEDI) |
MedImmune got rights to XmAb engineered antibody Fc domains for creating antibody candidates against tumor targets |
Xencor gets an up-front payment and is eligible to receive additional commercial license fees, milestone payments and royalties on any sales (12/7) |
Xcyte Therapies Inc. (XCYT) |
Invitrogen Corp. (IVGN) |
Invitrogen is acquiring Xcyte's T-cell expansion technology, known as the Xcellerate Process |
Xcyte gets $5M and a percentage of any sublicensing revenue; the deal includes data generated through various trials of the Xcellerated T Cells product (12/15) |
ZGene A/S* (Denmark) |
Lentigen Corp.* |
Lentigen got exclusive rights to certain ZGene multisubstrate kinase genes for certain indications |
Lentigen intends to create lentiviral vectors with increased safety features; ZGene is entitled to up-front, milestone and royalty payments (1/9) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
# Item occurred before the time frame of this chart but was not included in the previous chart. | |||
Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vienna Stock Exchange. | |||
